Overview on the use of recombinant human thyrotropin in thyroid cancer of follicular cell origin

Minerva Endocrinologica

Volumn 33, Issue 2, 2008, Pages 53-65

  Zanotti Fregonara, P ^a   Toubert, M E ^b   Taieb, D ^c   Ravasi, L ^a   Rubello, D ^d   Hindie, E ^b  

^a SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c TIMONE HOSPITAL   (France)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Hypothyroidism; Thyroid neoplasms; Thyrotropin

Indexed keywords

RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN; RECOMBINANT PROTEIN; THYROTROPIN;

BONE PAIN; CANCER THERAPY; CLINICAL TRIAL; DIAGNOSTIC VALUE; HEADACHE; HUMAN; HYPOTHYROIDISM; METASTASIS; NAUSEA; NEUROLOGIC DISEASE; PARESTHESIA; RESPIRATORY TRACT DISEASE; REVIEW; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN BLOOD LEVEL; THYROID FOLLICULAR CARCINOMA; WHOLE BODY SCINTISCANNING; QUALITY OF LIFE; THYROID TUMOR; TREATMENT OUTCOME;

CARCINOMA, PAPILLARY, FOLLICULAR; HUMANS; QUALITY OF LIFE; RECOMBINANT PROTEINS; THYROID NEOPLASMS; THYROTROPIN; TREATMENT OUTCOME;

EID: 47549111595     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447-63.
2. Melliere D, Hindie E, Becquemin JP, Desgranges P, Allaire E, Geachan E. Differentiated thyroid carcinoma - how to improve the long-term results? Twenty-five-year outcomes of 850 patients. Bull Acad Natl Med 2006;190:89-106. (Pubitemid 44024172)
3. Cady B, Conn K, Rossi RL, Sedgwick CE, Meissner WA, Werber J et al. The effect of thyroid hormone administration upon survival in patients with differentiated thyroid carcinoma. Surgery 1983;94:978-83. (Pubitemid 14208790)
4. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433-41. (Pubitemid 36623351)
5. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297-306. (Pubitemid 28065257)
6. Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin- stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 2005;90:5047-57.
7. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004;150:105-12.
8. Edmonds CJ, Hayes S, Kermode JC, Thompson BD. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. Br J Radiol 1977;50:799-807. (Pubitemid 8212220)
9. Robbins J. Pharmacology of bovine and human thyrotropin: an historical perspective. Thyroid 1999;9:451-3. (Pubitemid 29244922)
10. Thotakura NR, Desai RK, Bates LG, Cole ES, Pratt BM, Weintraub BD. Biological activity and metabolic clearance of a recombinant human thyrotropin produced in Chinese hamster ovary cells. Endocrinology 1991;128:341-8.
11. Torres MS, Ramirez L, Simkin PH, Braverman LE, Emerson CH. Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. J Clin Endocrinol Metab 2001;86:1660-4.
12. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997;337:888-96.
13. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999;84:3877-85. (Pubitemid 30644169)
14. Weintraub BD, Szkudlinski MW. Development and in vitro characterization of human recombinant thyrotropin. Thyroid 1999;9:447-50.
15. Meier CA, Braverman LE, Ebner SA, Veronikis I, Daniels GH, Ross DS et al. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 1994;78:188-96. (Pubitemid 24026771)
16. Taïeb D, Lussato D, Mundler O. Subcutaneous administration of recombinant human thyrotropin as an alternative to thyroid hormone withdrawal in patients with anticoagulated thyroid cancer: preliminary results. Thyroid 2004;14:463-4. (Pubitemid 38868767)
17. Zanotti-Fregonara P, Duron F, Keller I, Khoury A, Devaux JY, Hindié E. Stimulation test in the follow-up of thyroid cancer: plasma rhTSH levels are dependent on body weight, not endogenously stimulated TSH values. Nucl Med Commun 2007;28:257-9. (Pubitemid 46673201)
18. Vitale G, Lupoli GA, Ciccarelli A, Lucariello A, Fittipaldi MR, Fonderico F et al. Influence of body surface area on serum peak thyrotropin (TSH) levels after recombinant human TSH administration. J Clin Endocrinol Metab 2003;88:1319-22. (Pubitemid 36337796)
19. Castagna MG, Pinchera A, Marsili A, Giannetti M, Molinaro E, Fierabracci P et al. Influence of human body composition on serum peak thyrotropin (TSH) after recombinant human TSH administration in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2005;90:4047-50. (Pubitemid 41058170)
20. Montesano T, Durante C, Attard M, Crocetti U, Meringolo D, Bruno R et al. Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer. Biomed Pharmacother 2007;61:468-71. (Pubitemid 47393607)
21. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 2000;85:175-8. (Pubitemid 32268810)
22. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002;87:1499-501. (Pubitemid 34615228)
23. Torlontano M, Crocetti U, D'Aloiso L, Bonfitto N, Di Giorgio A, Modoni S et al. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. Eur J Endocrinol 2003;148:19-24. (Pubitemid 36176000)
24. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002;87:1490-8.
25. Park HM, Perkins OW, Edmondson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 1994;4:49-54. (Pubitemid 24145887)
26. Robbins RJ, Tuttle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein RA et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001;86:619-25.
27. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 2006;91:878-84. (Pubitemid 43357753)
28. Schlumberger M, Ricard M, Pacini F. Clinical use of recombinant human TSH in thyroid cancer patients. Eur J Endocrinol 2000;143:557-63.
29. Wartofsky L. Using baseline and recombinant human TSH-stimulated Tg measurements to manage thyroid cancer without diagnostic (131)I scanning. J Clin Endocrinol Metab 2002;87:1486-9.
30. Mazzaferri EL, Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer 2002;9:227-47. (Pubitemid 36240764)
31. David A, Blotta A, Rossi R, Zatelli MC, Bondanelli M, Roti E et al. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma. Thyroid 2005;15:158-64. (Pubitemid 40344365)
32. Castagna MG, Brilli L, Pilli T, Montanaro A, Cipri C, Fioravanti C et al. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab 2008;93:76-81.
33. Zanotti-Fregonara P, Khoury A, Duron F, Keller I, Christin-Maître S, Kiffel T et al. Which thyroid cancer patients need periodic stimulation tests? Eur J Nucl Med Mol Imaging 2007;34:541-6.
34. Smallridge RC, Meek SE, Morgan MA, Gates GS, Fox TP, Grebe S et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 2007;92:82-7. (Pubitemid 46075007)
35. Persoon AC, Jager PL, Sluiter WJ, Plukker JT, Wolffenbuttel BH, Links TP. A sensitive Tg assay or rhTSH stimulated Tg: what's the best in the long-term follow-up of patients with differentiated thyroid carcinoma? PLoS ONE 2007;2:816.
36. Schlumberger M, Hitzel A, Toubert ME, Corone C, Troalen F, Schlageter MH et al. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab 2007;92:2487-9. (Pubitemid 47037347)
37. Schlumberger M, Ricard M, De Pouvourville G, Pacini F. How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer. Nat Clin Pract Endocrinol Metab 2007;3:641-50. (Pubitemid 47294435)
38. Pacini F, Molinaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C et al. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the post-surgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001;86:5686-90. (Pubitemid 33152608)
39. Pacini F, Lippi F. Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): serum thyroglobulin measurement. J Endocrinol Invest 1999;22(Suppl):25-9.
40. Mazzaferri EL. Treating high thyroglobulin with radioiodine: a magic bullet or a shot in the dark? J Clin Endocrinol Metab 1995;80:1485-7.
41. Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab 2001;86:4092-7.
42. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995;80:1488-92.
43. Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin- stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 2005;90:5047-57.
44. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003;88:3668-73. (Pubitemid 37034512)
45. 131I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone. J Nucl Med 2001;42:1470-5. (Pubitemid 32953125)
46. Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT. Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid 2002;12:37-43.
47. Wartofsky L. RhTSH-Stimulated Thyroglobulin Study Group. Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. Thyroid 2002;12:583-90.
48. Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 2002;87:3242-7.
49. Eustatia-Rutten CF, Smit JW, Romijn JA, van der Kleij-Corssmit EP, Pereira AM, Stokkel MP et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf) 2004;61:61-74.
50. Luster M, Felbinger R, Dietlein M, Reiners C. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid 2005;15:1147-55. (Pubitemid 41720721)
51. Borget I, Corone C, Nocaudie M, Allyn M, Iacobelli S, Schlumberger M et al. Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal. Eur J Endocrinol 2007;156:531-8. (Pubitemid 46796519)
52. Mernagh P, Campbell S, Dietlein M, Luster M, Mazzaferri E, Weston AR. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. Eur J Endocrinol 2006;155:405-14. (Pubitemid 44463946)
53. Palmedo H, Bucerius J, Joe A, Strunk H, Hording N, Meyka S et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 2006;47:616-24. (Pubitemid 46768462)
54. Petrich T, Börner AR, Otto D, Hofmann M, Knapp WH. Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2002;29:641-7.
55. Chin BB, Patel P, Cohade C, Ewertz M, Wahl R, Ladenson P. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2004;89:91-5. (Pubitemid 38183865)
56. Saab G, Driedger AA, Pavlosky W, McDonald T, Wong CY, Yoo J et al. Thyroid-stimulating hormone-stimulated fused positron emission tomography/computed tomography in the evaluation of recurrence in 131I-negative papillary thyroid carcinoma. Thyroid 2006;16:267-72.
57. Leboulleux S, Schroeder PR, Schlumberger M, Ladenson PW. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract Endocrinol Metab 2007;3:112-21. (Pubitemid 46146964)
58. 131I ablation for papillary and follicular thyroid carcinoma. Thyroid 1997;7:265-71.
59. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 1983;309:937-41.
60. Robbins RJ, Turtle RM, Sonenberg M, Shaha A, Sharaf R, Robbins H et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 2001;11:865-9. (Pubitemid 32847944)
61. Pacini F, Molinaro E, Castagna MG, Lippi F, Ceccarelli C, Agate L et al. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002;87:4063-8.
62. Degroot LJ, Reilly M. Comparison of 30- and 50-mCi doses of iodine-131 for thyroid ablation. Ann Intern Med 1982;96:51-3. (Pubitemid 12205516)
63. Menzel C, Kranert WT, Döbert N, Diehl M, Fietz T, Hamscho N et al. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I. J Nucl Med 2003;44:1065-8. (Pubitemid 39663381)
64. Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 2006;47:648-54. (Pubitemid 46768466)
65. Robbins RJ, Larson SM, Sinha N, Shaha A, Divgi C, Pentlow KS et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med 2002;43:1482-8. (Pubitemid 35285874)
66. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006;91:926-32. (Pubitemid 43357760)
67. Pilli T, Brianzoni E, Capoccetti F, Castagna MG, Fattori S, Poggiu A et al. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 2007;92:3542-6.
68. Barbara D, Boni G, Meucci G, Simi U, Lapi P, Orsini P et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 2003;88:4110-5. (Pubitemid 37153707)
69. Pitoia F, Degrossi OJ, Niepomniszcze H. Why should the radioiodine dose be different in patients with differentiated thyroid carcinoma prepared with recombinant human TSH? Eur J Nucl Med Mol Imaging 2004;31:924. (Pubitemid 38758362)
70. Lazar V, Bidart JM, Caillou B, Mahé C, Lacroix L, Filetti S et al. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 1999;84:3228-34. (Pubitemid 30646949)
71. Schlesinger T, Flower MA, McCready VR. Radiation dose assessments in radioiodine (131I) therapy. 1. The necessity for in vivo quantitation and dosimetry in the treatment of carcinoma of the thyroid. Radiother Oncol 1989;14:35-41.
72. Hindié E, Zanotti-Fregonara P, Keller I, Duron F, Devaux JY, Calzada-Nocaudie M et al. Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome. Endocr Relat Cancer 2007;14:799-807. (Pubitemid 350074068)
73. Rudavsky AZ, Freeman LM. Treatment of scan-negative, thyroglobulin- positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone. J Clin Endocrinol Metab 1997;82:11-4.
74. Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 1997;82:3637-42.
75. Perros P. Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience. J Endocrinol Invest 1999;22(11 Suppl):30-4.
76. Masiukiewicz US, Nakchbandi IA, Stewart AF, Inzucchi SE. Papillary thyroid carcinoma metastatic to the pituitary gland. Thyroid 1999;9:1023-7.
77. Lippi F, Capezzone M, Angelini F, Taddei D, Molinaro E, Pinchera A et al. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. Eur J Endocrinol 2001;144:5-11. (Pubitemid 32126906)
78. Berg G, Lindstedt G, Suurküla M, Jansson S. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest 2002;25:44-52. (Pubitemid 34168339)
79. Jarzab B, Handkiewicz-Junak D, Roskosz J, Puch Z, Wygoda Z, Kukulska A et al. Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients. Eur J Nucl Med Mol Imaging 2003;30:1077-86.
80. Braga M, Ringel MD, Cooper DS. Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. J Clin Endocrinol Metab 2001;86:5148-51. (Pubitemid 33070229)
81. Goldberg LD, Ditchek NT. Thyroid carcinoma with spinal cord compression. JAMA 1981;245:953-4.
82. Lukinac L, Franceschi M, Nöthig-Hus D, Lechpammer S, Tomasić J, Vranesić B et al. Endogenously labeled thyroid hormones (131I-T3/T4) in sera of patients with differentiated thyroid carcinoma. Thyroid 1996;6:201-6. (Pubitemid 26279412)
83. Moog F, Linke R, Manthey N, Tiling R, Knesewitsch P, Tatsch K et al. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 2000;41:1989-95. (Pubitemid 32038687)
84. Luster M, Lassmann M, Haenscheid H, Michalowski U, Incerti C, Reiners C. Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab 2000;85:3640-5.
85. Mariani G, Ferdeghini M, Augeri C, Villa G, Taddei GZ, Scopinaro G et al. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer. Cancer Biother Radiopharm 2000;15:211-7. (Pubitemid 30305974)
86. Robbins RJ, Driedger A, Magner J. U.S. and Canadian Thyrogen Compassionate Use Program Investigator Group. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid 2006;16:1121-30.
87. Robbins RJ, Voelker E, Wang W, Macapinlac HA, Larson SM. Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: case report and review of literature. Endocr Pract 2000;6:460-4.
88. Rotman-Pikielny P, Reynolds JC, Barker WC, Yen PM, Skarulis MC, Sarlis NJ. Recombinant human thyrotropin for the diagnosis and treatment of a highly functional metastatic struma ovarii. J Clin Endocrinol Metab 2000;85:237-44. (Pubitemid 32268820)
89. Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C et al. RhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer 2005;12:49-64. (Pubitemid 40477087)
90. Driedger AA, Kotowycz N. Two cases of thyroid carcinoma that were not stimulated by recombinant human thyrotropin. J Clin Endocrinol Metab 2004;89:585-90. (Pubitemid 38269862)
91. Taïeb D, Jacob T, Zotian E, Mundler O. Lack of efficacy of recombinant human thyrotropin versus thyroid hormone withdrawal for radioiodine therapy imaging in a patient with differentiated thyroid carcinoma lung metastases. Thyroid 2004;14:465-7. (Pubitemid 38868768)
92. Brabant G, Maenhaut C, Köhrle J, Scheumann G, Dralle H, Hoang-Vu C et al. Human thyrotropin receptor gene: expression in thyroid tumors and correlation to markers of thyroid differentiation and dedifferentiation. Mol Cell Endocrinol 1991;82:7-12.
93. Pötzi C, Moameni A, Karanikas G, Preitfellner J, Becherer A, Pirich C et al. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. Clin Endocrinol (Oxf) 2006;65:519-23. (Pubitemid 44414277)
94. Haq M, Harmer C. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome. Clin Endocrinol (Oxf) 2005;63:87-93. (Pubitemid 40966408)
95. Hindié E, Mellière D, Lange F, Hallaj I, de Labriolle-Vaylet C, Jeanguillaume C et al. Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? Eur J Nucl Med Mol Imaging 2003;30:974-81.